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Abstract
Background: The East/West gradient in health across Europe has been described often, but not
using metrics as comprehensive and comparable as those of the Global Burden of Disease 2000
and Comparative Risk Assessment studies.
Methods: Comparisons are made across 3 epidemiological subregions of the WHO region for
Europe – A (very low child and adult mortality), B (low child and low adult mortality) and C (low
child and high adult mortality) – with populations in 2000 of 412, 218 and 243 millions respectively,
and using the following measures: 1. Probabilities of death by sex and causal group across 7 age
intervals; 2. Loss of healthy life (DALYs) to diseases and injuries per thousand population; 3. Loss
of healthy life (DALYs) attributable to selected risk factors across 3 age ranges.
Results: Absolute differences in mortality are most marked in males and in younger adults, and for
deaths from vascular diseases and from injuries. Dominant contributions to east-west differences
come from the nutritional/physiological group of risk factors (blood pressure, cholesterol
concentration, body mass index, low fruit and vegetable consumption and inactivity) contributing
to vascular disease and from the legal drugs – tobacco and alcohol.
Conclusion: The main requirements for reducing excess health losses in the east of Europe are:
1) favorable shifts in all amenable vascular risk factors (irrespective of their current levels) by
population-wide and personal measures; 2) intensified tobacco control; 3) reduced alcohol
consumption and injury control strategies (for example, for road traffic injuries). Cost effective
strategies are broadly known but local institutional support for them needs strengthening.
Background
The evolving picture of East-West disparities in health
indicators across Europe have been documented in terms
of life expectancy [1] and premature mortality [2] and in
terms of death rates for major contributing causes [3,4]. In
addition to aggregate or partial mortality measures, a
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eases and injuries, and their risk factors, is a valuable
guide to strategies for improving health and for reducing
cross-population health differentials. An important aspect
of such comparative analyses is the use of a consistent and
comparable metric of lost healthy life and the attribution
of such losses either to diseases or injuries or to the risk
factors for those diseases and injuries. The Global Burden
of Disease project for the year 2000 (GBD2000) [5] and
the associated Comparative Risk Assessment (CRA)
Project [6], use common metrics and comparable meth-
odology to address the burden of disease and injuries and
their risk factors. We use the databases (some only
recently available [6]) and published results from this
study, to evaluate the nature and reasons for the health
disparities across Europe. The results are presented for 3
epidemiologically-defined subregions of the WHO region
for Europe.
In analyzing the causes of the marked differences in health
levels across Europe, we have deliberately restricted our
scope to the more proximal determinants ('risk factors'),
because knowledge of their role is more secure and lends
itself more readily to quantitative analysis.
Methods
Populations
Following the Burden of Disease protocols, the WHO
region for Europe (which extends to Israel, Turkey and the
former Soviet republics of central Asia) is divided into 3
'sub-regions' on the basis of child and adult mortality lev-
els – Europe A (very low child; very low adult mortality)
with a population in 2000 of 412 millions, Europe B (low
child, low adult mortality) population 218 millions and
Europe C (low child and high adult mortality) with a pop-
ulation of 243 millions. These 'subregions' are neither
contiguous nor culturally homogeneous and correspond
only approximately to western Europe, Eastern Europe
and the successor states to the Soviet Union. Table 1 lists
the countries within each subregion.
Mortality and burden of disease
Detailed methods for the Global Burden of Disease
(GBD) 2000 project are described elsewhere [5]. In sum-
mary, for 14 epidemiological regions of the world, includ-
ing 3 in Europe, GBD 2000 provides estimates of
mortality and burden of disease for over 130 diseases and
injuries. Mortality data are from national vital registration
systems, reported annually to the World Health Organiza-
tion. For countries in the European region with incom-
plete mortality data, or, more commonly, with substantial
proportions of deaths allocated to non-specific codes [7],
demographic techniques and epidemiological models are
used to estimate mortality by age, sex, and cause. We cal-
culated probabilites of death within age intervals from
groups of causes using life table methods [8].
Burden of disease is expressed in disability-adjusted life
years (DALYs), an aggregate measure of loss of healthy life
to either premature mortality or to non-fatal illness or
injury [9]. Inputs used to estimate losses of healthy life
include estimates of disease incidence and/or prevalence,
severity, and duration, generally from systematic reviews
of disease-specific epidemiological literature or disease-
specific registries (e.g. cancer registries). Flows of lost
healthy life extending to future years are discounted and
weighted by the age at which the lost healthy life would
have been lived. The conceptual issues and sensitivity of
results to these methodological details on the estimates of
DALYs lost are described elsewhere [10].
Risk factors
The methods and data sources for the Comparative Risk
Assessment project are described elsewhere [6,11]. In
summary, the contribution of a risk factor to disease or
mortality relative to some alternative exposure scenario
(i.e. population attributable fraction, PAF, defined as the
proportional reduction in population disease or mortality
that would occur if exposure to the risk factor were
reduced to an alternative exposure scenario [12-14]) is
given by the generalized "potential impact fraction" in
Table 1: Global Burden of Disease sub-regions in Europe
Mortality stratum Countries
A Very low child; very low adult Andorra, Austria, Belgium, Croatia, Czech Republic, Denmark, Finland, France, Germany, Greece, Iceland, 
Ireland, Israel, Italy, Luxembourg, Malta, Monaco, Netherlands, Norway, Portugal, San Marino, Slovenia, Spain, 
Sweden, Switzerland, United Kingdom
B Low child, low adult Albania, Armenia, Azerbaijan, Bosnia and Herzegovina, Bulgaria, Georgia, Kyrgyzstan, Poland, Romania, 
Slovakia, Tajikistan, The Former Yugoslav Republic of Macedonia, Turkey, Turkmenistan, Uzbekistan, 
Yugoslavia
C Low child, high adult Belarus, Estonia, Hungary, Kazakhstan, Latvia, Lithuania, Republic of Moldova, Russian Federation, UkrainePage 2 of 10
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tion attributable fraction is then multiplied by total
deaths or burden of disease to estimate risk factor attrib-
utable mortality or burden of disease.
where
RR(x): relative risk at exposure level x
P(x): population distribution of exposure
P'(x): counterfactual distribution of exposure
m: maximum exposure level
The estimates of burden of disease and injuries due to risk
factors in the CRA project are based on a counterfactual
exposure distribution that would (within the limits of cur-
rent knowledge and data) result in the lowest population
risk, irrespective of whether attainable using current inter-
ventions or policies. This is referred to as the theoretical-
minimum-risk exposure distribution [15,16]. The theoretical-
minimum-risk exposure distribution was zero for risk fac-
tors for which zero exposure could be defined and
reflected minimum risk (e.g. no smoking). For some risk
factors, zero exposure was an inappropriate choice
because of physical lower limits to exposure reduction
(e.g. particles in ambient air). For physiological risk fac-
tors such as blood pressure, where lower values are associ-
ated with lower risk, the lowest values reliably associated
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Table 2: 10 leading risk factors for the European region, exposure variables, theoretical minima, and contributions to total disease 
burden in the European region (source: Table 1 and Figure 1 in Ezzati et al. 1). See Table 1 in Ezzati et al. 1 for disease outcomes and 
data sources.
Risk Factor Exposure Variable Theoretical Minimum Contribution to European 
disease burden (%GBD)
High blood pressure Level of systolic blood pressure 115 SD 6 mmHg 12.8%
Tobacco Current levels of smoking impact ratio 
(indirect indicator of accumulated 
smoking risk based on excess lung cancer 
mortality); oral tobacco use prevalence
No tobacco use 12.3%
Alcohol Current alcohol consumption volumes 
and patterns
No alcohol use b 10.1%
High cholesterol Level of total blood cholesterol 3.8 SD 1 mmol/l (147 SD 39 mg/dl) 8.7%
High body mass index (BMI) Body mass index, BMI (height over weight 
squared)
21 SD 1 kg/m2 7.8%
Low fruit and vegetable intake Fruit and vegetable intake per day 600 g (SD 50 g) intake per day for 
adults
4.4%
Physical inactivity Three categories of inactive, insufficiently 
active (<2.5 hours per week of 
moderate-intensity activity, or less than 
4000 KJ/week), and sufficiently active. 
Activity in discretionary-time, work, and 
transport considered
All having at least 2.5 hours per 
week of moderate-intensity 
activity or equivalent (400 KJ/
week)
3.5%
Illicit drugs Use of amphetamine, cocaine, heroin or 
other opioids and intravenous drug use
No illicit drug use 1.6%
Lead Current blood lead levels 0.016 µg/dl blood lead levels c 0.8%
Unsafe sex Sex with an infected partner without any 
measures to prevent infection 
(represented as parameters of an HIV 
model)
No unsafe sex 0.7%
a The resulting haemoglobin levels vary across regions and age-sex groups (from 11.66 g/dl in under-5 children in SEAR-D to >14.5 g/dl in adult 
males in developed countries) because the other risks for anaemia (e.g. malaria) vary.
b Theoretical minimum for alcohol is zero, the global theoretical minimum. Specific sub-groups may have a non-zero theoretical minimum.
c Theoretical minimum for lead is the blood lead levels expected at background exposure levels. Health effects were quantified for blood lead levels 
above 5 µg/dl where epidemiological studies have quantified hazards.Page 3 of 10
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theoretical-minimum-risk exposure distribution. Alcohol
has benefits as well as harms depending on the disease
under consideration and the patterns of alcohol con-
sumption. A counterfactual exposure distribution of zero
was still the default choice for alcohol, however, in some
regions (e.g. EUR-A) effects on vascular disease were esti-
mated as negative (protective) and combined with haz-
ardous effects on other diseases to derive an estimated net
effect [17]. For details of the risk factors considered see
Table 2.
Results
The increase in mortality risks, by age group, from Europe
A to B to C is illustrated in Figure 1. The most striking dif-
ferences across the three subregions occur between ages
15 and 59. For example, for 30 year old males, the risk of
death before reaching 45 in Europe B is twice that in
Europe A, and in Europe C, nearly 5 times that in Europe
A. For females, the relative mortality differences between
Europe B and A are broadly similar, across all age inter-
vals, to those for males, but mortality levels in Europe C
are closer to those in Europe B than is the case for males.
For example at ages 30 to 45 the risk of death in Europe C
relative to Europe A is 2.8 fold for females compared to 5
fold for males. Beyond age 60, mortality risks in Europe B
females are much closer to those in Europe C than to
those in Europe A.
In males below age 60, gradients are present for all dis-
eases but the biggest contributors to subregional differ-
ences are injuries (up to 8 fold differences between Europe
C and A) and vascular diseases. Vascular diseases generally
make the biggest absolute contributions to differences in
mortality risks. In the age range 45 to 59, for example,
risks of vascular death are 3 to 4 fold higher in B relative
to A and 4 to 5 fold higher in C relative to A. Interestingly,
relative differences are slightly greater in females (see Fig-
ure 1). Beyond age 60 in males, cancer and communicable
diseases are not important contributors to mortality dif-
ferences between subregions.
Figure 2 shows the estimated losses of healthy life from
the 15 leading causes of disease burden in Europe as a
whole. For several causes – unipolar depressive disorders,
adult onset hearing loss, osteoarthritis and for two condi-
tions primarily caused by smoking: chronic obstructive
pulmonary disease and lung cancer – the magnitude of
health loss (DALYs) is comparable across the 3 sub-
regions. Age-specific mortality data show, however, that
the rough equality of male burdens from lung cancer
results from a balancing of higher risks in Europe B and C
Probability of death within age intervals from 6 groups of causes by sex: Europe A, B and C, 2000Figure 1
Probability of death within age intervals from 6 groups of causes by sex: Europe A, B and C, 2000.
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a consequence of the historic lag of the smoking epidemic
in Europe B and C compared to A.
The burdens experienced in Euro B and C in excess of
those in Euro A come predominantly from 2 clusters of
diseases: from vascular diseases (a gradient from 42 to 68
to 125 DALYs/thousand people/year from A to B to C
when ischaemic heart disease, cerebrovascular disease and
other cardiac diseases are combined for both sexes) and
injuries (a gradient from 16 to 26 to 50 DALYs/thousand
people/year from A to B to C when road traffic accidents,
self-inflicted injuries and other unintentional injuries are
combined for both sexes).
The burden of disease attributable to leading risk factors
in the 3 regions is shown in Figure 3. There is a substantial
step down from the health losses attributed to the 7th
ranking cause, physical inactivity, to those attributed to
the 8th, illicit drugs. The 7 leading risk factors can be
divided into 2 clusters: a nutritional/physiological group
contributing especially to risk of vascular disease – blood
pressure, blood cholesterol concentration, body mass
index, BMI (serving as an operational measure for excess
adiposity), low fruit and vegetable consumption and
physical inactivity. The second group comprises the major
legal drugs – tobacco and alcohol.
Burden of disease due to 15 leading diseases or disease clusters in 2000: crude rates of DALYs per thousand population for E ope A, B and C, ordered by ranking for the combined European regionFigur 2
Burden of disease due to 15 leading diseases or disease clusters in 2000: crude rates of DALYs per thousand 
population for Europe A, B and C, ordered by ranking for the combined European region. Other cardiac diseases 
are those not classified as rheumatic, hypertensive, ischaemic or inflammatory. Other digestive diseases are those not classified 
as peptic ulcer, cirrhosis of the liver or appendicitis. Other unintentional injuries are those not classified as motor vehicle acci-
dents, poisonings, falls, fires or drownings.
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ences vary more by age and sex than do the contributions
of the nutritional/physiological group of risk factors.
Much larger burdens are attributed to alcohol in males in
Europe C, most strongly between ages 15 and 44, than in
the other 2 subregions. Alcohol's contribution in Europe
B is likely reduced by the proportion living in predomi-
nantly muslim states (Turkey and Uzbekistan alone
account for more than a third of the population of Europe
B and both are low alcohol consumers [18]).
Smoking contributes powerfully to the increases in dis-
ease burdens in males (but not in females) as one moves
from Europe A to B to C. Further, the differences in male
disease burdens attributed to smoking are relatively
greater for streams of lost healthy life (DALYs) that begin
in middle age and earlier: In the age range 45 to 59 the
ratio of burdens attributable to smoking in Europe B to
those in Europe A is around 2 fold and for C relative to A
is around 3.5 fold. By contrast for males aged 60+ burdens
attributable to smoking are comparable in B and A and
less than 2 fold higher in C. Two factors are likely contrib-
uting to the greater differences in male burdens from
smoking in middle rather than old age: i) very high
tobacco consumption among younger men in in many
countries in Europe B and most in Europe C, because of
the historical lag in the decline in male smoking in Europe
B and C relative to Europe A and; ii) the steeper gradient
in vascular risks at younger ages, during which smoking
acts as a more powerful multiplier than at higher ages.
The nutritional/physiological group of risk factors all
show strong gradients in their attributed burdens across
the 3 sub-regions, and assumedly account for much of the
East-West gradient in premature vascular disease in both
sexes (see also Discussion).
About half the DALYs attributed to smoking in Europe C
are from vascular disease (because its multiplier effect is
acting on very high background risks for vascular dis-
eases), compared to just over a quarter in Europe A (where
Burden of disease due to 10 leading risk factors: DALYs per thousand total population for Europe A, B and C, by sex and age group*Fig re 3
Burden of disease due to 10 leading risk factors: DALYs per thousand total population for Europe A, B and C, 
by sex and age group*. * DALYs are assigned to the age of death or of incidence (and not to the age at which the lost 
healthy life would have been lived)
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fallen markedly since the 1960s) [19]. Therefore, the mag-
nitude of health losses from smoking, dominated by vas-
cular diseases in the more disadvantaged European
subregions, is strongly affected by the nutritional and
physiological risk factors, much more so than vice versa.
This multiplicative combination of multiple causes
explains why such a large gradient exists in total burdens
attributed to smoking whilst the gradient for lung cancer
is more modest (Figure 2). Whilst the differences in bur-
dens attributed to alcohol are much greater in younger
adult males, the large differences in burdens attributed to
the nutritional/physiological group of risk factors extend
across all age-sex groups – making them responsible for a
larger share of East-West health differences overall. At the
same time, given the large hazards of alcohol on injuries
and neuropsychiatric diseases, which are not affected by
the other risks considered, measures to reduce health
losses from alcohol will be important components of
reducing East-West health differentials in Europe.
Discussion
We have identified three risk factor/disease clusters as
leading modifiable causes of excess health losses in
Europe B and C: first, in order of importance, is the 'nutri-
tional/physiological' group of risk factors (blood pressure,
blood cholesterol concentration, body mass index, low
fruit and vegetable consumption and physical inactivity)
contributing primarily to very large absolute differences in
vascular disease burdens; second, and largely because of
its important multiplier effect on vascular risks, is
tobacco; and third is the role of alcohol and other contrib-
utors to injuries as major sources of differences in health
experiences of adult males.
This is the first report summarising differences in health
levels and health determinants across Europe using results
of the GBD2000 and CRA. The unique and central
strength of the methods employed here is their ability to
compare and rank the burdens of ill-health caused by dif-
ferent diseases and injuries and to similarly compare and
rank the established causes of these diseases and injuries.
The metrics we have used have been developed to favour
comprehensiveness and comparability – not ease of pre-
cise measurement. In particular, estimates of the 'years
lived with disability' (YLD) component of the DALY are
subject to significant uncertainty. This is because data for
calculating time spent in non-fatal health states are less
available than death registrations and because non-fatal
health states require valuation before they can be incorpo-
rated into summary measures. In Europe as a whole, the
'years lived with disability' (YLD) component accounts for
about 45% of DALYs lost. Findings as to the relative con-
tributions of different diseases and injuries to subregional
differences in levels of health are, however, robust to the
uncertainty intrinsic to YLD estimates, because differen-
tials are dominated by vascular diseases and injuries with
large YLL component.
Despite 4 years of systematic data collection and analysis,
leading sources of uncertainty for our findings on risk fac-
tors based on the CRA project are likely to be the esti-
mated effects of alcohol on injury burden,
neuropsychiatric conditions and vascular disease (mainly
due to the heterogeneity of hazards across populations),
and the estimated contributions of risk factors such as low
fruit and vegetable consumption and physical inactivity to
vascular risks (due to difficulties in defining and measur-
ing exposure). Estimates for the hazards attributable to
risk factors such as blood pressure, blood cholesterol con-
centration, body mass index and tobacco are likely to be
more secure, drawing, as they do, on very large bodies of
knowledge.
There is continuing scientific uncertainty about the ability
of the classic risk factors such as those included in the CRA
to adequately account for the high level [20] and temporal
variation [3] in vascular disease rates, especially in Europe
C. Several candidate risk factors, including neuro-humor-
ally mediated exposures ('stress'), have been advanced to
fill this explanatory gap [21,22]. CRA risk factors have,
however, been deliberately limited to those 'for which
there was good potential for satisfactory quantification of
population exposure distributions and health effects
using existing scientific evidence and available data ...' [6]
(p xx) – criteria which excluded such candidates, as well as
other nutritional risks that require valid data on dietary
composition. Despite the potentially important role of
these other factors, vascular risk in individuals is related
similarly to the classic risk factors across cultures with
widely differing risk factor levels [23,24] making them
appropriate, albeit not exclusive, targets for public health
policy cross-nationally, even if other, currently less well
understood, influences are also contributing to differ-
ences in national levels and trends.
Because of multicausality and because multiple causes
magnify each other's hazards (in a multiplicative way in
standard epidemiological models), the contribution of
any given risk factor to (absolute) disease burdens
depends heavily on the other risks with which it is com-
bining. For example, the burden of disease attributable to
suboptimal cholesterol concentrations is over 3 times
higher (in relation to population) in Europe C compared
to Europe A (Figure 3) even though mean cholesterol con-
centrations are not higher in Europe C [25]. This combi-
nation of multiple risks implies that it is the absolute level
of disease risks rather than the levels of individual risk fac-
tors that should determine the intensity of the publicPage 7 of 10
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are high, as in Europe B and C, the leading public health
priority must be to reduce all amenable vascular risk factors
irrespective of their starting levels using complementary indi-
vidual-level and population-wide strategies. An indication
of the potential for such interventions is the decline over
the past decade and a half in premature vascular deaths,
most notably in females, in some former communist
countries [26]. Recent rates of decline in countries such as
Slovenia, Poland and the Czech Republic have been
greater than in Europe A as a whole (unpublished obser-
vations).
The appropriate mix of 'high risk' and 'population' strate-
gies for each country will depend on the resources availa-
ble for medical care and on institutional capacities.
Reducing risk in high risk individuals may be achieved by
preventive counselling and changes in lifestyle and by
'chemoprevention' (eg long term medication to lower
blood pressure and blood cholesterol concentrations).
'High risk' strategies relying on 'chemoprevention' will
however, have much less effect on population disease bur-
dens than 'population' strategies, unless large proportions
of the adult population are placed on preventive medica-
tions [27].
Given the greater potential effectiveness of population
approaches and the constraints on implementing high
risk approaches, it will generally be preferable to start with
population wide measures such as public education on
the known causes of heart attack and stroke, and eco-
nomic and regulatory approaches to help lower salt con-
sumption and saturated fat consumption and to increase
fruit and vegetable consumption, along with increased
physical activity levels [28].
The second requirement, and potential, for health conver-
gence across Europe is a decline in tobacco consumption
in Europe B and C. Trends in some parts of Europe B are
again encouraging, with all 8 new EU member states in
Eastern Europe showing falling male lung cancer mortal-
ity in early middle age, since at least the mid 1990s [29].
The rise in smoking in young women has also been
reversed in Poland [30]. Further East, in Russia, Belarus
and the Ukraine there is sustained high smoking preva-
lence in males and rising prevalence in young females [31]
– pointing to an urgent need to intensify control measures
in those countries. The role of tobacco in levels and distri-
butions of health across Europe is particularly important
because economic (e.g. taxes) and regulatory (compre-
hensive advertising restrictions and bans on smoking in
public places) measures have been shown to be highly
effective in smoking reduction in many countries [32].
The third cluster to be addressed to reduce health inequal-
ities across Europe is that of alcohol and injuries. The
alcohol – injury cluster imposes particularly heavy bur-
dens on Europe C males, especially under the age or 44
(Figure 3). Injuries account for over half the health loss
atttributed to alcohol in Europe C males; and 43% of the
health loss from injuries in this group is attributable to
alcohol [17]. Recent economic analyses indicate (assum-
ing generalisability of findings from studies done else-
where) that an optimally cost effective strategy for
averting overall harms to health from hazardous alcohol
use in Europe C would be the combination of a 50%
increase in tax, a ban on advertising and brief advice from
physicians [33]. In addition to programmes to reduce
alcohol consumption, effective means of reducing road
traffic injuries are known, including the control of driving
under the influence of alcohol which in Europe C males is
estimated to account for 64% of traffic deaths.
The former communist countries dealt well with the pub-
lic health challenges they faced in the period immediately
following the second world war [34]. They failed however,
to respond effectively to the more complex challenges
posed by chronic disease and injury. These failures con-
tributed to one of the gravest tragedies at the latter 20th
century – the loss of 2.5 – 3.0 million lives in Russia alone
during the 1990s in excess of the losses expected at 1991
mortality levels [4]. The failure to develop public health
infrastructures appropriate to the challenges faced, will
have contributed substantially to these tragedies. Low
rates of scientific publication in priority fields such as car-
diovascular disease suggest serious under-investment in
research of strategic importance to public health efforts:
Medline indexed publication rates on cardiovascular dis-
eases (per million population) are 7 fold lower in Europe
B compared to Europe A and 7 fold lower again in Europe
C (calculated from data in [35]). Low levels of relevant sci-
entific activity will have provided little stimulus for the
mass media to help raise public knowledge of chronic dis-
ease risks. Knowledge of established risk factors for vascu-
lar disease has been found to be low in Bulgarian [36] and
Polish [37] populations. Remedial action is needed to
address these infrastructural weaknesses throughout
much of Europe B and all of Europe C if future public
health endeavours are to be commensurate with the chal-
lenges faced.
The diseases and risk factors identified in this analysis also
point to important data gaps and future research needs for
using combinations of preventive and therapeutic inter-
ventions to reduce health disparities across Europe. These
include: local analyses in the countries of Europe B and C
to better define country-specific hazards for alcohol
(including, for example, reasons for the very high mortal-
ity from liver cirrhosis in countries such as Hungary); bet-Page 8 of 10
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BMC Public Health 2005, 5:116 http://www.biomedcentral.com/1471-2458/5/116ter indicators and data on physical activity, diet and
nutritional risks that can be used for identifying interven-
tions; data on multi-risk correlation within countries
(which is important for better quantification of hazards,
for designing intervention packages for related risks and
for within country equity); to develop scenarios for inter-
vention packages and delivery options (including cost-
effectiveness); to characterise local institutional strengths
and weaknesses; and to assess risk reversibility.
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